Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MAP2 | P11137 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.35 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3218751 | 0.90 | BTK (0.40) | MAP2PARP1GRM2 | |
| SCHEMBL3207821 | 0.90 | ABL1 (0.44) | CSF1RPARP1PLAUCHEK1 | |
| SCHEMBL9885160 | 0.85 | GSK3B (0.42) | GSK3BCSF1RPARP1 | |
| SCHEMBL3206124 | 0.85 | FEN1 (0.44) | GSK3BCHEK2 | |
| SCHEMBL3217348 | 0.84 | KIF11 (0.48) | GSK3BCSF1RCHEK2CHEK1 | |
| SCHEMBL3212694 | 0.84 | MAP2 (0.42) | MAP2CHEK2HDAC2 | |
| SCHEMBL3215596 | 0.84 | TNKS2 (0.45) | GSK3BCHEK2FLT3 | |
| SCHEMBL3836025 | 0.83 | MYC (0.53) | GSK3BGRM2MYCCHEK1 | |
| SCHEMBL3206899 | 0.82 | GSK3B (0.43) | GSK3BHDAC2 | |
| SCHEMBL13613324 | 0.82 | KIF11 (0.40) | CSF1RCHEK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2119703-B1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193237-B2 | Indole derivative having IκB kinase β inhibitory activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2119703-A1 | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041628-A1 | NOVEL INDOLE DERIVATIVE HAVING IKAPPAB KINASE BETA INHIBITORY ACTIVITY | NFKBIA, IKBKB, IKBKG | GSK3B 278/4885MAP2 964/4885CSF1R 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.